Zoetis Inc. (NYSE:ZTS) Shares Bought by Resources Management Corp CT ADV

Resources Management Corp CT ADV raised its stake in Zoetis Inc. (NYSE:ZTS) by 7.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,313 shares of the company’s stock after purchasing an additional 1,049 shares during the period. Resources Management Corp CT ADV’s holdings in Zoetis were worth $2,481,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Bank of Montreal Can raised its position in Zoetis by 0.3% in the 2nd quarter. Bank of Montreal Can now owns 1,121,131 shares of the company’s stock valued at $192,212,000 after purchasing an additional 3,637 shares in the last quarter. Lombard Odier Asset Management Europe Ltd acquired a new stake in shares of Zoetis during the 2nd quarter worth about $3,560,000. Public Sector Pension Investment Board raised its position in shares of Zoetis by 69.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 17,281 shares of the company’s stock worth $2,996,000 after acquiring an additional 7,061 shares in the last quarter. Steel Grove Capital Advisors LLC raised its position in shares of Zoetis by 37.2% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 1,734 shares of the company’s stock worth $301,000 after acquiring an additional 470 shares in the last quarter. Finally, J. Stern & Co. LLP raised its position in shares of Zoetis by 4.1% during the 2nd quarter. J. Stern & Co. LLP now owns 189,147 shares of the company’s stock worth $32,791,000 after acquiring an additional 7,515 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $220.38.

Zoetis Stock Performance

NYSE ZTS opened at $193.59 on Tuesday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market cap of $88.33 billion, a price-to-earnings ratio of 37.30, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The business has a fifty day moving average of $185.01 and a 200-day moving average of $174.42. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.41 earnings per share. As a group, analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.